NextGen Life Sciences Impact Fund I

Investing in
human health

ABOUT

We combine sustainable growth with attractive returns

We speed up the development of transformative therapies

We facilitate global access to innovative health care

We push forward European innovations in life sciences

WHAT WE DO

Invest in up-coming companies that develop innovative drugs and products to improve human health

The “NextGen Life Sciences Impact Fund I” provides early-stage and growth equity to companies in Europe mainly in the DACH region. The focus lies on the fast-growing markets of biotechnology, medical technology, and digital health.

All investments are done in accordance with sustainability standards and selected impact criteria. The fund especially aims to contribute to the Sustainable Development Goal #3 „Good Health and Well-Being“

Biotechnology

Biopharmaceutical companies with a pipeline of proprietary product candidates

Biotech companies with an innovative technology platform enabling in-house pipeline buildup and partnering deals within the industry

MEDICAL TECHNOLOGY

Medical Device companies with products in development or close to market entry

Diagnostics companies developing innovative methods and tests to translate discoveries in disease biology into early and reliable diagnostics

DIGITAL HEALTH

Companies that combine advances in Artificial Intelligence (AI) and Machine Learning to develop novel technologies transforming single or multiple steps of the pharma value chain

Combine relevant industry expertise with tailored financing strategies

Identify investment opportunities early

NextGen Capital Partners has excellent sourcing capabilities, as we have operationally collaborated with life sciences start-ups and large corporates for the last 20 years on R&D, go to market and financing strategy

Hands-on investment management

Through our deep understanding of early-stage companies from more than 300 managing and mentoring projects, we collaborate as proficient partner with our portfolio companies

Leveraging an experienced team

Besides building an in-house investment management team, NextGen Capital Partners is advised by a high caliber advisory board represented by industry experts 

Efficient deployment of capital and timely exists

The well-balanced mix of early-stage and growth financings will result in timely exit opportunities within the investment phase

Delivery of real-world impact

In addition to an intense focus on ESG philosophy and practise instilled into our portfolio companies, NextGen Capital Partners applies detailed and measurable impact goals which are tailored to each investment

TEAM

Industry expertise and international business-network

The management team capitalizes on 40+ years of sector expertise and is advised by acknowledged experts from universities, institutes and the pharma industry.

Michael Kring

Managing Partner

Peggy Entorf-Krauch

Managing Partner

FOR INVESTORS

Fund future champions in life sciences and make the world a better place

“NextGen Life Sciences Impact Fund I” is a closed special AIF registered in Luxembourg and will in total invest Euro 350 million in privately owned companies. The runway of the fund is 12 years. We are convinced that sustainable growth can be achieved in parallel with attractive financial returns and integrate ESG factors and impact metrics into our investment process.

As an investor you have the opportunity to:

N

Participate in unique investment opportunities in growth areas of the life sciences industry

N

Benefit from deep industry expertise and track record in company building and growing

N

Help to develop sustainable solutions to improve patients‘ life and well-being

For Entrepreneurs

Build future champions in life sciences and make the world a better place

Through the NextGen Life Sciences Impact Fund I entrepreneurs get access to early-stage and growth funding provided by a dedicated team. We act as lead- and co-investor and take an active mentoring role to enhance individual company performance.

As an entrepreneur you benefit from:

N

Lean funding process driven by fast-decision making and taking a lead role in consortium building

N

Active mentoring helping you to build and grow your company in accordance with ESG standards

N

Long-term commitment that implies early entry and subsequent follow-on financing support

Be part of next generation investing and do something meaningful

MAIL: info@nextgenlifesciences.com | TELEPHONE: +49 89 51 51 97 72